Transcatheter aortic valve replacement (TAVR) has revolutionized the management of severe aortic stenosis (AS), with indications expanding from high and intermediate- to low-surgical risk patients. However, the durability of transcatheter heart valves (THV) is still an ongoing concern, especially in younger, low-risk patients. Redo-TAVR (TAVR-in-TAVR) is feasible and is associated with favorable short-term outcomes in observational studies and registries. Understanding native aortic valve (AV) anatomy and the characteristics of the index THV is critical to the technical and procedural success of redo-TAVR. Cardiac computed tomography angiography (CTA) plays a central role in pre-procedure planning and aids in appropriate valve selection and procedural planning in addition to identifying patients at high risk for coronary occlusion during redo-TAVR. While evidence on redo-TAVR is limited to retrospective observational studies, prospective registries will shed light on the long-term clinical and hemodynamic outcomes.
Untreated clinically significant aortic regurgitation (AR) is frequently seen in the general population and is associated with worse outcomes, including higher mortality. Surgical aortic valve replacement is currently the treatment of choice for severe AR. However, a significant proportion of these patients are not good surgical candidates due to advanced age, frailty, and underlying comorbidities, prompting the need for transcatheter options. Current guidelines do not recommend transcatheter aortic valve replacement (TAVR) for severe AR with commercially available transcatheter heart valves (THVs). Off-label use of commercial TAVR devices has been associated with lower procedural success, increased complications, mainly valve embolization and residual AR, and poor clinical outcomes. The suboptimal results of TAVR with the current generation THVs are attributed to anatomical factors such as a lack of annular calcium, a large aortic annulus, and a dilated aortic root, posing challenges for device anchoring. TAVR with dedicated devices for AR, such as the JenaValve and the J-Valve, is rapidly evolving, with preliminary evidence suggesting higher procedural success rates and improved clinical outcomes during short-term follow-up. There is a significant unmet need for the development of transcatheter therapies with dedicated THVs for severe AR, and both the JenaValve and J-Valve systems are undergoing rigorous clinical trial testing before regulatory approval in the United States.
• The first year after regulatory approval of transcatheter tricuspid repair and replacement devices, we observed a significant increase in tricuspid regurgitation referrals, advanced cardiac imaging testing, and procedural volumes.
Mitral transcatheter edge-to-edge repair (M-TEER) in the setting of prior transcatheter aortic valve replacement (TAVR) and severe mitral annular calcification (MAC) can pose procedural challenges. We describe the case of an 82-year-old woman with prior TAVR (29 mm EVOLUT FX+; Medtronic), P2 flail, and heavy circumferential MAC underwent M-TEER with the PASCAL Ace device (Edwards Lifesciences). This case illustrates that M-TEER can be performed safely and effectively in anatomies complicated by severe MAC and prior TAVR with careful preprocedural planning, intraprocedural imaging, and operator experience.